Literature DB >> 2493791

Taste reactivity analysis of 6-hydroxydopamine-induced aphagia: implications for arousal and anhedonia hypotheses of dopamine function.

K C Berridge1, I L Venier, T E Robinson.   

Abstract

The deficits in feeding and drinking that result from 6-hydroxydopamine (6-OHDA) lesions of the mesostriatal dopamine system are often explained using either sensorimotor arousal or anhedonia hypotheses. Sensorimotor arousal hypotheses posit that dopamine systems facilitate the capacity of sensory stimuli to activate any motor output. The anhedonia hypothesis suggests that dopamine systems amplify the hedonic impact of positive reinforcers. Natural palatability-dependent ingestive and aversive actions, which are emitted by rats to tastes, provide a sensitive test that can discriminate between these hypotheses: A reduction of sensorimotor arousal should diminish the ability of tastes to elicit any actions, whereas anhedonia should shift the balance between positive and aversive actions. To directly compare these two hypotheses, taste reactivity was examined in rats made aphagic by intranigral 6-OHDA injections. The results did not support either of these predictions: Taste reactivity was essentially unchanged. The persistence of normal taste reactivity argues against both an anhedonia and a global sensorimotor arousal interpretation and provides further evidence that the capacity for hedonics can be neurologically dissociated from motivated appetitive behavior. An incentive attribution hypothesis that can account for the results is discussed, along with its implications for a wide range of phenomena associated with dopamine depletion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493791     DOI: 10.1037//0735-7044.103.1.36

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  54 in total

1.  Metabotropic glutamate receptor blockade in nucleus accumbens shell shifts affective valence towards fear and disgust.

Authors:  Jocelyn M Richard; Kent C Berridge
Journal:  Eur J Neurosci       Date:  2010-12-29       Impact factor: 3.386

Review 2.  Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine.

Authors:  Paul E M Phillips; Mark E Walton; Thomas C Jhou
Journal:  Psychopharmacology (Berl)       Date:  2006-11-22       Impact factor: 4.530

Review 3.  Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding.

Authors:  Brian A Baldo; Ann E Kelley
Journal:  Psychopharmacology (Berl)       Date:  2007-02-23       Impact factor: 4.530

Review 4.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 5.  Dissecting motivational circuitry to understand substance abuse.

Authors:  Robert A Wheeler; Regina M Carelli
Journal:  Neuropharmacology       Date:  2008-06-25       Impact factor: 5.250

6.  Ingestion and emotional health.

Authors:  N K Dess
Journal:  Hum Nat       Date:  1991-09

Review 7.  Phasic dopamine release in appetitive behaviors and drug addiction.

Authors:  Matthew J Wanat; Ingo Willuhn; Jeremy J Clark; Paul E M Phillips
Journal:  Curr Drug Abuse Rev       Date:  2009-05

Review 8.  Role of brain dopamine in food reward and reinforcement.

Authors:  Roy A Wise
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 9.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  Worth the 'EEfRT'? The effort expenditure for rewards task as an objective measure of motivation and anhedonia.

Authors:  Michael T Treadway; Joshua W Buckholtz; Ashley N Schwartzman; Warren E Lambert; David H Zald
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.